|
Carroll, M; Ohno-Jones, S; Tamura, S et al. (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-52
|
|
Druker, B J; Tamura, S; Buchdunger, E et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-6
|
|
Jain, S K; Susa, M; Keeler, M L et al. (1996) PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88:1542-50
|
|
Oda, T; Tamura, S; Matsuguchi, T et al. (1995) The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia 9:295-301
|
|
Carlesso, N; Griffin, J D; Druker, B J (1994) Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9:149-56
|
|
Oda, T; Heaney, C; Hagopian, J R et al. (1994) Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-8
|
|
Avalos, B R; Broudy, V C; Ceselski, S K et al. (1994) Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. Blood 84:789-94
|
|
Druker, B J; Neumann, M; Okuda, K et al. (1994) rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. J Biol Chem 269:5387-90
|
|
Epstein, R J; Druker, B J; Roberts, T M et al. (1992) Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci U S A 89:10435-9
|
|
Druker, B J; Sibert, L; Roberts, T M (1992) Polyomavirus middle T-antigen NPTY mutants. J Virol 66:5770-6
|
